Alembic Pharmaceuticals has recently informed exchanges that the company has successfully completed a USFDA inspection of its Oncology Formulation Facility (F-2) in Panelav with no Form 483 observations. The inspection took conducted between October 7th to 8th, 2024.
In the exchange filing, Alembic Pharmaceuticals shared, “The company has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Oncology (Injectable and Oral Solid) Formulation Facility (F-2) located at Panelav. The inspection was successfully completed without any Form 483 observation. The inspection was conducted from 7 th October, 2024 to 8th October, 2024.”